Inflammation

Driving Innovation in Inflammation Therapeutics

Acute inflammation is the body’s natural response to injury, initiating the healing process through immune cell activity. However, this response can unfortunately become chronic, as is seen in conditions such as rheumatoid arthritis, lupus, and allergies. Chronic inflammation occurs when immune cells continue to respond unchecked even after the original injury has healed, resulting in persistent inflammatory conditions. Addressing these challenges through innovative drug discovery research is crucial to developing effective therapeutics that can modulate the inflammatory response and restore health.

Benefits of Choosing Eurofins Discovery for Inflammation Research

At Eurofins Discovery, our team of experts boasts extensive knowledge and experience in inflammation research with a successful track record of advancing multiple clinical candidates, leveraging our comprehensive expertise from in vitro to in vivo. Our translational approach spans from target-based biochemical and cellular assays to disease-relevant primary cellular systems. We specialize in:

  • Identifying key target modulation biomarkers
  • Establishing clear PK/PD relationships through biomarker measurement
  • Demonstrating efficacy in our in vivo pharmacology models
  • Flexible pricing models, both Fee-for-Service (FFS) and Full Time Equivalent (FTE) solutions available

Partnering with us ensures expert guidance and flexibility throughout your inflammatory disease program, facilitating rapid and efficient project progression.

Contact Us to Move Your Inflammation Research Forward

With our innovative solutions and deep understanding of inflammatory diseases, Eurofins Discovery is your ideal partner for inflammation drug discovery. Contact us today to learn how we can help you achieve your research goals and expedite the discovery of effective therapeutics.
 

Key Areas

Your organization may have a novel target, pathway, or phenotype of interest, or a new approach in a well-explored area—along with challenges in program implementation.

Our state-of-the-art scientific resources reveal the potential of your small molecules in every research phase, from early discovery and hit finding to lead optimization and preclinical testing. Our global team of experts will keep your end goal of approval and adoption in view while delivering robust, data-driven insights that focus your decision-making.

Our chemistry services drive preclinical success by combining synthetic, computational, medicinal, and analytical chemistry with biology, delivering optimized molecules through an integrated, data-driven approach. With labs located strategically in Spain, US & India, we provide flexible Chemistry services to accelerate your Drug Discovery program.

Phenotypic drug discovery gives you a head start on clinical success with translationally relevant biomarkers as functional readouts for insights on mechanism of action, efficacy, and toxicity assessments.

The BioMAP® Platform provides response profiles in human primary cell-based disease models. A robust reference database powers advanced analytics.

Evaluate mechanistic and functional readouts. By testing candidates in diverse cellular contexts with ELISA, Alpha LISA, Meso Scale Discovery®, Luminex, and more.

Small molecule or biotherapeutics assessment on adaptive immunity with BioMAP T Cell Autoimmune Panel, Cytokine Storm, and AdapTive models.

The generic approach to target disease-causing proteins is through small molecules that bind to and inhibit the enzymatic activity of the protein.

Features